Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials
I'm PortAI, I can summarize articles.
Viatris announced FDA approval for octreotide acetate, a generic version of Sandostatin LAR Depot, for treating acromegaly and certain tumors. The FDA also cleared MR-146 for neurotrophic keratopathy clinical trials. Viatris plans a phase 1/2 trial in H1 2026. Additionally, regulatory milestones were achieved for a low-dose estrogen patch in the US and pitolisant in Japan, with applications under review for contraception and obstructive sleep apnea, respectively.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments